广东华南疫苗

South China Vaccine (SCV) is a clinical-stage biotechnology company based in Guangzhou, China, specializing in the research, development, and industrialization of recombinant protein vaccines. The company utilizes a proprietary insect cell-based Baculovirus Expression Vector System (BEVS) to develop complex multi-valent vaccines targeting significant public health threats. Its lead programs include high-valence HPV vaccines, notably a 14-valent candidate designed to provide broader protection against cervical cancer than existing products. SCV also maintains a pipeline targeting influenza, rotavirus, and other infectious diseases, supported by large-scale GMP manufacturing capabilities. The company aims to provide high-quality, affordable vaccine solutions through advanced biopharmaceutical engineering.